Vancouver’s AbCellera has acquired Boston’s TetraGenetics, a biotech company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins. The acquisition was an all-cash transaction one that includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial milestone payments related to […]
AbCellera
Life Sciences BC Announces Annual Award Winners
British Columbia has a vibrant and thriving life sciences industry that is distinguished not only by local and national accomplishments, but also by international recognition. Life Sciences BC has announced the recipients of the 23rd Annual Life Sciences BC Awards which recognize the talented individuals and organizations who contribute to the vibrant life sciences ecosystem […]
Connecting The Dots: July 2021
Each month, Kathleen Reid (Founder + Managing Director at Switchboard Public Relations) connects the dots between the trends, headlines and narratives that are informing the BC tech sector. Following a two-month hiatus, she resumes CTD’s regular monthly schedule by shedding light on BC Tech’s New Economy Report, recent acquisitions by BC’s biggest tech companies, and […]
Canada Highlights Support For Innovation In British Columbia
As Canadians begin to look toward economic recovery, Canada’s small and medium-sized enterprises (SME) will be the backbone of economic growth in communities across the country. These firms are already supporting more than 10 million jobs for Canadian workers, and many of them are making groundbreaking discoveries to improve Canadians’ lives and drive innovation and technology. To […]
AbCellera To Build Manufacturing Facility Within Walking Distance Of New HQ
AbCellera has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new antibody therapies to clinical trials, supporting Canada’s efforts to respond quickly […]
AbCellera Breaks Ground on Global Headquarters in Vancouver
Vancouver’s AbCellera announced today that it has broken ground on an expanded global headquarters in Vancouver in anticipation of adding hundreds of employees to its current 250-person workforce over the next few years. “We’re building state-of-the-art facilities in Vancouver to accelerate the development of new antibody therapies with biotech and pharma partners from around the world,” […]
The New Ventures BC Startup Competition Is Back
The New Ventures BC Competition, presented by Innovate BC is back and searching for BC’s best new tech startups. For the 21st year, New Ventures BC is giving away over $250,000 in non-dilutive cash and prizes to the most promising tech ventures across the province. Why enter the 2021 New Ventures BC Competition? It’s more than […]
AbCellera Plans To Hire Hundreds In Vancouver
Vancouver’s AbCellera emerged last year as a leading early stage company in the race to bring COVID-19 treatments to market when their Pandemic Prevention Platform team brought the first COVID-19 antibody to clinical trials in under 90 days. Their herculean efforts were acknowledged when the pharmaceutical upstart was named the winner of Fast Company’s Innovative Team […]
Peter Thiel Joins AbCellera’s Board of Directors
Vancouver’s AbCellera announced today the appointment of Peter Thiel to its Board of Directors. AbCellera is a privately held technology company with an antibody discovery platform that searches, decodes, and analyzes natural immune systems to find antibodies that can be used to prevent and treat disease. Earlier this year Thiel was part of an investor […]
AbCellera Expands Technology Stack with Acquisition of Trianni
Vancouver’s AbCellera has acquired Trianni in an all-cash transaction valued at US $90 million. Trianni’s genetic engineering technology is a platform for developing humanized mice. The acquisition deepens AbCellera’s technology stack with a suite of genetically engineered mice for generating diverse panels of human antibodies with drug-like properties. “Trianni marks our fourth and largest strategic […]